Clinical trials: Stage II Rectal Cancer
Metastatic Colorectal Cancer
Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
Since its introduction, 5-fluorouracil (5-FU) has been the cornerstone of treatment for metastatic colorectal cancer (mCRC). Meanwhile the oral 5FU pro-drug Capecitabine (Xeloda®) proved equivalence to 5-FU and is a well…
- Trial name
- PASSION (NCT02119026)
- Testing
- Capecitabine, Bevacizumab, Oxaliplatin
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Prof. Dr. Werner Scheithauer
Anal Cancer
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00423293
- Testing
- fluorouracil, mitomycin C, Intensity-modulated radiation therapy
- Where
- 172 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Radiation Therapy Oncology Group
Neoplasm Metastasis, Colorectal Cancer
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor…
- Trial name
- OPUS (NCT00125034)
- Testing
- Cetuximab, Oxaliplatin
- Where
- 78 sites in Austria, Belgium and 11 more
- Volunteers
- 344 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00551421
- Testing
- pertuzumab, cetuximab, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously…
- Trial name
- NCT01298570
- Testing
- Regorafenib (BAY 73-4506), FOLFIRI
- Where
- 24 sites in United States, Ireland
- Volunteers
- 181 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury
Lovastatin may protect against late effects of radiation therapy in patients with prostate cancer
- Trial name
- NCT00580970
- Testing
- lovastatin
- Where
- 3 sites in United States
- Volunteers
- 73 people
- Sponsor
- Virginia Commonwealth University
BRAF V600E-mutant Metastatic Colorectal Cancer
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received…
- Trial name
- ANCHOR-CRC (NCT03693170)
- Testing
- encorafenib, Binimetinib, Cetuximab
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 95 people
- Sponsor
- Pierre Fabre Medicament
Colorectal Cancer
A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer
The purpose of the study is to describe the tumor response rates for the two regimens being studied, and to determine how long patients live after receiving the treatment, how long patients are without return of their disease…
- Trial name
- NCT00192075
- Testing
- Gemcitabine, avastin, 5FU/folinic acid
- Where
- 15 sites in United States
- Volunteers
- 84 people
- Sponsor
- Eli Lilly and Company
Liver Metastases, Recurrent Colon Cancer
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well giving combination chemotherapy and bevacizumab before surgery and radiolabeled monoclonal antibody therapy works in treating liver metastases in patients with metastatic colorectal cancer.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer
- Trial name
- NCT01320683
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Locally Advanced Rectal Cancer
Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer
Phase II clinical trial, open-label, randomized, two arms, multicentre (possibly multinational). Academic, investigator initiated.
- Trial name
- AXEBEAM (NCT00828672)
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- 9 sites in Belgium
- Volunteers
- 84 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colorectal Cancer
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
This is a multi-institutional, single arm, open-label, phase II study, including a safety run-in cohort. No randomization or blinding involved.
- Trial name
- NCT02375672
- Testing
- Pembrolizumab, mFOLFOX6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hoosier Cancer Research Network
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Colorectal Cancer, Liver Neoplasms
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus…
- Trial name
- NCT00149396
- Testing
- NV1020
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediGene
Colorectal Neoplasms
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
The intensity of tumour response appears to be correlated with the feasibility and the duration of a therapeutic pause or of a reduced maintenance therapy maintained until progression in patients initially controlled by so-called…
- Trial name
- HIGH-LIGHT (NCT02842580)
- Testing
- 5 FLUOROURACYL, acide folinique, irinotecan
- Where
- 11 sites in France
- Volunteers
- 21 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Lung Cancer, Tobacco Use Disorder
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population.
- Conditions
- Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer
- Trial name
- NCT01434342
- Testing
- Nicotine Replacement Patch
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Metastatic (Stage IV) Colorectal Cancer
A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
The present trial is designed to determine whether pre-treatment with PledOx lowers the frequency and severity of side effects from FOLFOX6 administration in patients with metastatic colorectal cancer.
- Trial name
- PLIANT (NCT01619423)
- Testing
- PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg)
- Where
- 33 sites in United States, Bulgaria and 6 more
- Volunteers
- 186 people
- Sponsor
- Egetis Therapeutics AB (publ)
Metastatic Colorectal Cancer
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
- Trial name
- NCT01927341
- Testing
- MEK162, Panitumumab
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Rectal Cancer
Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
Preoperative induction chemotherapy has been successfully used in a variety of malignancies and provides several advantages over postoperative therapy.
- Trial name
- NCT00216086
- Testing
- Capecitabine, Irinotecan, EUS
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Gabi Chiorean, MD
Colorectal Cancer
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00416494
- Testing
- bevacizumab, oxaliplatin, Capecitabine
- Volunteers
- 50 people
- Sponsor
- Herbert Hurwitz, MD
Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
This randomized phase II trial studies how well capecitabine and bevacizumab with or without atezolizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places.
- Conditions
- Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7
- Trial name
- NCT02873195
- Testing
- Atezolizumab, Bevacizumab, Capecitabine
- Where
- 10 sites in United States
- Volunteers
- 133 people
- Sponsor
- Academic and Community Cancer Research United